



RESEARCH PAPER

OPEN ACCESS

The role of 5-HT₁ receptors of central amygdala upon ACPA-induced anxiolytic-like behaviors and amnesia in rat

Saba Taheri¹, Shahrbanoo Oryan², Mohammad-Reza Zarrindast^{3,4*}, Ameneh Rezayof⁵

¹Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran

²Department of Biology, Faculty of Basic Sciences, Kharazmi University, Tehran, Iran

³Iranian National Center for Addiction Studies, Tehran University of Medical Sciences, Tehran, Iran

⁴School of Cognitive Sciences, Institute for Research in Fundamental Sciences (IPM), Tehran, Iran

⁵Department of Animal Physiology, School of Biology, College of Science, University of Tehran, Iran

Key words: ACPA, anxiety, memory, serotonergic system.

<http://dx.doi.org/10.12692/ijb/5.12.40-57>

Article published on December 15, 2014

Abstract

Cannabinoidergic as well as serotonergic systems of the amygdala modulates anxiety like behaviors and emotional memory. The effects of cannabinergic system on the anxiety and learning process relate to the central amygdala and its interaction with serotonergic system have not studied yet. With the aim of evaluating the regulating effects of cerotonergic system on the anxiolytic effects of cannabinoids and the possibility of restoring cannabinoid caused amnesia by certonergetic system, the current research was conducted using the elevated plus-maze (EPM) test-retest paradigm in the male mice. The bilateral guide-cannulae were implanted to allow intra-CeA microinjection of serotonergic agents. The formation of emotional memory was declined by intra-CeA injection of ACPA, but the anxiety reaction was not affected by the various doses of the mentioned substance. Intra-CeA injection of CP94253 Hydrochloride, a 5-HT₁ serotonin receptor agonist, diminished the formation of emotional memory and the locomotor activity, while 5-HT₁ serotonin receptor antagonist, did not influence the anxiety-like behaviors and the emotional memory formation. According to the obtained findings from the current research, it seems that ACPA may trigger anxiolytic-like behaviors and prevent the emotional memory formation, mainly via the activation and deactivation of the CeA 5-HT₁ serotonin receptors.

* **Corresponding Author:** Mohammad-Reza Zarrindast ✉ zarinmr@ams.ac.ir

Introduction

Without doubt learning is regarded as one of the most important mental process. Learning literally occurs via experiment and exercise resulting in permanent alterations in behaviors, not reactions like, exhausting or adaptation to darkness (Heimer and Van Hoesen, 2006). In fact, the brain capability to save past experiments, events and better acclimation in the future is considered as its main characteristic. Sensory input located in the prefrontal cortex, from cortex to hippocampus and parahippocampus of the limbic system are of the importance in learning.

In human and animals, anxiety is a warning signal about the possible occurrence of danger, thereby preparing to counteract a threat (Belzung, 2001). According to the definition presented by Barlow (2002), anxiety is different from the fear; anxiety directs future behavioral reactions related to the possible close unfavorable events, whereas the fear is a warning response to exist danger felt (Davis, 2006). A cascade of biochemical and endocrine process are triggered by anxiety and stress, physiologically complicated reactions in organisms (Nutt *et al.*, 2001).

Cannabinoids with the vast pharmacological effects in human and other mammals are effective drugs in the *central nervous system* (CNS). There are two well known receptors, CB1 and CB2, for cannabinoids. CB1 receptors concentrate in the central zone and mediate many cannabinoid related effects (Hajos and Freund, 2006). CB1 receptors belonging to Gprotein-coupled family (Nasehi *et al.*, 2010) diffuse vastly in cortex, basal ganglia and amygdale, as well as its implications in the physiological and behavioral actions of cannabinoid have been well documented (Zarrindast *et al.*, 2012). In addition, recently the existence of receptors called CB3 in the nervous system has been reported (Begg *et al.*, 2005). As the activation of the endocannabinoid system occurred under the learning state modulates synaptic plasticity during the initiation process, the injection of the selective antagonist, adversely interacts with the mentioned system (De Oliveira Alvares *et al.*, 2005).

Endocannabinoids act a critical neuromodulatory role in many behavioral related reactions, including movement, anxiety, learning and memory (Lichtman *et al.*, 2002; Pacher *et al.*, 2006). The studies conducted on the mice with gene deficiencies in CB1 receptors revealed that excitements in CB1 receptors caused by cannabinoids were responsible for the memory destruction and cannabinoid system may facilitate amnesia (Varvel and Lichtman, 2002). Also, the recorded symptoms of anxiety in mice lack of CB1 receptors (Zarrindast *et al.*, 2010) and anxiety responses resulted from the application of cannabinoid ligands (Rezayof *et al.*, 2010) confirm this hypothesis that endocannabinoids are involved in the expression of anxiety behaviors (Ghiasvand *et al.*, 2009; Ghiasvand *et al.*, 2011), the destruction in short term memory, the spatial learning and anxiety-like behaviors (Zarrindast *et al.*, 2010; Degroot *et al.*, 2005; Lichtman, 2002).

Serotonin plays vital roles in the physiological and pathological process. Transportation of serotonin possesses crucial effects in the control and regulation of mood, impulse, sleep, eating, libido and cognitive functions like learning and memory, mainly via serotonin receptors. As some of the agonists of the 5-HT₁ receptor have anxiolytic effects (Nasehi *et al.*, 2010), this receptor implicates in the occurrence of anxiety disturbances. Also the function of 5HT₁ of the selective ligand had the sufficient influence in the various tests related to the learning and memory (Smith *et al.*, 1999; Luttgen *et al.*, 2005). At least, fifteen presynaptic and postsynaptic serotonin receptors have been so far known, classified in seven families based on their structure, activation and affinity to the different ligands as well as called 5HT₁R to 5HT₇R (Bruss *et al.*, 2000). These receptors, which are G-coupled protein, leave out for 5HT₃R activates adenylyl cyclase, the enzyme responsible for producing of CAMP, thereby increasing the activity of CAMP-dependent protein kinase (Miquel *et al.*, 1995).

The phosphorylation of the involved enzymes by these protein kinases modulate the activity of the ion channels and consequently depolarization of

serotonin receptors occur. G_i -coupled 5-HT₁ inhibits adenylyl cyclase, thereby hyperpolarizing 5-HT₁. G_q -coupled 5-HT₂ activates phospholipase C (Lam *et al.*, 2010). At least two types of serotonin receptors, including 5-HT_{1A}, B located intensively in hippocampus, amygdala and raphe nucleus are implicated in the expression of behaviors related to learning and anxiety (Luttgen *et al.*, 2005; Madjid *et al.*, 2006; Zarrindast *et al.*, 2010). It has been stated that vast varieties of cognitive functions, including reward, feeling, learning, memory, attention and thought correlate by amygdala (Baxter *et al.*, 2006). The receptors of the both drug types, cannabinoid and serotonin, have similarity in intracellular signal transduction mechanism, reductions in cAMP, mainly via the activation of G_i proteins (Zarrindast *et al.*, 2010).

Amygdala possesses a key role in the regulation and control of autonomic neuroendocrine reactions and behavior related to the anxiety (Zarrindast *et al.*, 2010; Jafari *et al.*, 2007; Rezayof *et al.*, 2007). Central amygdala determines behaviors and alterations in hippocampus function related to stress and emotional memory (Schafe *et al.*, 2005). It has been proposed that the high expression rates of both cannabinoid and serotonin receptors in the amygdala, the interaction and correlation of these amygdala systems regulate anxiety and memory process (Casswell *et al.*, 1973; LeDoux, 1998; Marco *et al.*, 2009). The existence of neuronal cycle related to the anxiety behaviors and memory process in amygdala has been established by the implications of the basal lateral amygdala in the control of anxiety, fear and learning reactions (Sarkisyan *et al.*, 2009). The various brain structures seem to be involved in the regulation of different types of anxiety, memory and learning. One of the most critical zone in the control of anxiety related behaviors and learning reaction is Amygdala (Pellow *et al.*, 1986; Haj-Dahmane *et al.*, 2011). The key role of amygdala in the organization and appearance of anxiety and learning has been suggested based on the experimental evidences recorded in the different *in vitro* studies in various species of animals, such as rat (Moshfegh *et al.*, 2010;

Zarrindast *et al.*, 2011).

With the aim of evaluating the interaction between serotonergic receptors, located in the central amygdala, ACPA and the strong selective agonist of CB₁ cannabinoid receptors, the current research was conducted. The Elevated Plus Maze test has been applied for assessing anxiety like behaviors, whereas EPM method was used to study anxiety like behaviors as well as an emotional memory in the present research. There are some studies related to the effects of ACPA on anxiety process (Chegini *et al.*, 2014; Zarrindast *et al.*, 2008), however the effects of the cannabinergic system on the anxiety, memory and learning process relate to the central amygdala nucleus and its interaction with serotonergic system have not studied yet. Therefore With the aim of evaluating the regulating effects of serotonergic system on the anxiolytic effects of cannabinoids and the possibility of restoring cannabinoid caused amnesia by serotonergic system, the current research was conducted.

Material and methods

Male Wistar rats (250 - 300 g; Institute of pharmacology Studies, Tehran, Iran) were used in these experiments. Cages, four rats in each one, were incubated in the room in which the temperature was maintained at 23 ± 1 °C and the light: dark rhythm was controlled in a 12:12 h cycle. The animals were allowed to acclimate for seven days prior to the initiation of experiments. Eight animals were used in each experimental group. The experiments were carried out during the light phase of the cycle. Animals handling was limited to the time of home cage cleaning (each 48 h), weighing, and drugs administration only.

Drugs

The drugs used in the study were ketamine and xylazine (Alfasan Chemical Co, Woerden, Holland) for animal anesthesia. Other drugs which were supplied by Tocris, Bristol, UK were: CP94253 Hydrochloride selective 5-HT₁ agonist serotonin receptor; at 0.05, 0.5, 5 and 50 ng/rat), GR127935 Hydrochloride (a

selective 5-HT₁ receptor antagonist; at 0.05, 0.5, 5 and 50 ng/rat), and ACPA, Arachidonylcyclopropylamide (apotent and selective CB₁ receptor agonist; at 0.00025, 0.0005, 0.001, 0.002 µg/kg). All drugs were dissolved in sterile 0.9% saline, just before the experiments. 5-HT₁ receptor agents were administered into the CeA at the volume of 0.3 l/site, while ACPA injection was done intraperitoneally at 10 ml/kg. Control animals received saline. The infusion time and selected drug doses used in the experiments were chosen according to the pilot and published work in scientific literature (Paxinos and Watson., 2007; Motevasseli *et al.*, 2010; Nikseresht *et al.*, 2012).

Elevated plus-maze (EPM) apparatus

An EPM, made of Plexiglas and consisting of two opposite open-arms (50×10 cm) surrounded by a 1 cm high ledge, and two enclosed-arms (50×10×40 cm) was used. The maze was set up 50 cm above the floor. The junction area of the four arms (central platform) measured 10×10 cm (Zarrindast *et al.*, 2010; Eslimi *et al.*, 2011).

The Stereotactic surgery and drug infusion

Rats were intraperitoneally anesthetized using ketamine hydrochloride 10% (Alfasan, Woerden, Holland; 50 mg/kg) plus xylazine 2% (Alfasan, Woerden, Holland; 4 mg/kg) then positioned in a stereotactic frame. The upper incisor bar was set at 3.3 mm below the interaural line so that the skull aligned horizontally between bregma and lambda. Two bilateral guide-cannulae (through which an injection cannula could be inserted for drugs, saline or vehicle applications, 5-7 days later) were stereotactically implanted over the central amygdala. Taking bregma as the reference point, the coordinates for the central amygdala were AP = -2.2 mm, ML = ±4.2 mm and DV = -6 mm, according to the atlas of Paxinos and Watson (Motevasseli *et al.*, 2010; Zarrindast *et al.*, 2010; Eslimi *et al.*, 2011; Nikseresht *et al.*, 2012). The cannulae were fixed to the skull by means of acrylic resin and two stainless steel screws. By the end of the surgery, a stylet was introduced inside each guide cannula to reduce possible

occlusion. After the surgery, rats were placed again in their home cages in groups of five, similar to before surgery. Five to seven days post surgery, rats received a bilateral infusion into the central amygdala using dental needles (27-gauge) introduced through guide cannulae. The injection needles were advanced until their tips reached 1 or 2 mm below the cannulae end. Then, 0.3 µl/site of solutions were injected central amygdala each one. This was done during 60 s, using a 2.5-µl glass Hamilton syringe. A polyethylene catheter was interposed between the upper end of dental needles and the microsyringes. The displacement of an air bubble inside the polyethylene catheter was used to monitor the drug flow. To allow proper infusion, needles were removed 60 s after the completion of injection.

Modified behavioral testing

In the present study, EPM test-retest method was chosen to investigate anxiety and the aversive learning process. Recent studies have shown that using the test-retest sessions in the EPM, results in a qualitative shift in emotional state. Thus, unconditioned fear in the test session would possibly transform to a learnt avoidance during the retest (Cruz-Morales *et al.*, 2002; Gianlorenco *et al.*, 2011). In our study, animals were given a pretest intracerebral drug injection, followed by an injection free (undrugged) retest, 24 h later. Thus, drug effects on aversive learning with the subsequent long-term effects on memory, were tested 24 h later. It has been reported that prior experienced undrugged test session in the elevated plus-maze, alters behavioral responses in the retest drug-free session (Carvalho *et al.*, 2005; Stern *et al.*, 2010). It has also been suggested that EPM retest outcome depends on the test session length and the baseline anxiety state (Ghizoni *et al.*, 2006). Support for the former test-retest procedure stems from the data showing that although pretest systemic benzodiazepine administration reliably exerts anxiolytic effects, pre-retest injections fail to affect the response in the second EPM session (File *et al.*, 1993). In general, reduced open-arms exploratory behaviors of saline treated groups during retest session, indicates an

aversive learning associated with the initial exploration of this potentially dangerous environment.

All experiments were carried out in a minimally illuminated (40-lux) room, during the diurnal phase, between 9:00 AM and 15:00 PM. Five minute EPM sessions were recorded by a video camera while a monitor and a DVD-recording system were installed in the adjacent room. After each EPM session, the apparatus was cleaned and towel dried to avoid urine impregnation. The observer, who quietly sat one meter behind one of the closed arms of the maze, used chronometers to measure in the closed arms and the number of entries into the open and closed arms. Entry was considered only when all four paws were placed in the arms. The maze was cleaned with distilled water after each EPM session. The raw data were used to calculate the %OAT (Open Arm Time percentage), which is the percentage of time each mouse spent in the open arms relative to the total amount of time spent in any arm ($\text{open/total} \times 100$). %OAE (Open Arm Entries per-centage) was recorded as a correlate for the lack of aversive memory upon retest. The sum of all closed arm entries (CAE) was used as an index for the general locomotor activity. All data were obtained by observer (but not digital-recording system) after which the measures were calculated manually. The digital-recording system was used as backup in case of lost information (Casarrubea *et al.*, 2009; Eslimi *et al.*, 2011).

Verification of cannulae placements

Upon concluding each experiment, rats were deeply anesthetized after which 1% Methylene Blue solution was injected into the central amygdala (0.5 $\mu\text{l/side}$) as described in the drug section. Each animal was then decapitated, its brain removed and placed in a 10% formalin solution. After 7-10 days, the brains were sliced and the sites of injections were verified according to the atlas of Paxinos (Paxinos and Watson., 2007). Data from rats with cannulae placements outside the intended sites were excluded from the statistical analyses.

Statistical analysis

Given the normality of distribution and the homogeneity of variance, the results were statistically evaluated using the repeated measure and two-way analysis of variance (ANOVA), in which mean \pm S.E.M was employed for the comparison of outcomes between experimental groups and their corresponding controls.

Experimental design

Experiment 1

Open-arms exploratory behavior following pretest intra-central amygdala microinjections of ACPA

In order to substantiate that the intracentral amygdalamicroinjection of ACPA involves in anxiety and learning, the drug infusion took place 5 min prior to EPM testing. Naive rats were tested in the EPM, 5 min after concurrent intra- microinjection of saline (0.3 $\mu\text{l/rat}$); ACPA (0.00025, 0.0005, 0.001 and 0.002 $\mu\text{g/rat}$). To investigate the possible carryover, intra central amygdala ACPA effects on aversive learning during test session to aversive memory in retest. Treated groups were retested in EPM 24 h later, undrugged.

Experiment 2

Open-arms exploratory behavior following pretest intra-central amygdala microinjections of CP94253 Hydrochloride

In this experiment, the animals received concurrent intra-central amygdala microinjection of saline (0.3 $\mu\text{l/rat}$); CP94253 Hydrochloride(0.05, 0.5, 5 and 50ng/rat). Rats were tested in the EPM, 5 min after infusion. To investigate whether intra- central amygdala CP94253 Hydrochloride affects aversive memory acquisition, treated groups were retested in the EPM 24 h later, undrugged.

Experiment 3

the effect of subthreshold dose of CP94253 Hydrochloride in the central amygdala upon open-arms exploratory behaviors induced by ACPA in the central amygdala

Four groups of animals received concurrent intra-central amygdala microinjection of subthreshold dose

of CP94253 Hydrochloride (5 ng/rat, intracental amygdala) or different doses of ACPA (0.00025, 0.0005, 0.001 and 0.002 µg/rat). Rats were tested in the EPM, 5 min after infusion. Treated groups were then retested in EPM, 24 h later, undrugged.

Experiment 4

Open-arms exploratory behavior following pretest intra-central amygdala microinjections of GR127935 (5-HT₁ serotonin receptor antagonist)

In this experiment, the animals received concurrent intra-central amygdala microinjection of saline (0.3 µl/rat); GR127935 (0.05, 0.5, 5 and 50 ng/rat). Rats were tested in the EPM, 5 min after infusion. To investigate whether intra-central amygdala GR127935 affects aversive memory acquisition, treated groups were retested in the EPM 24 h later, undrugged.

Experiment 5

The effect of subthreshold dose of GR127935 in the central amygdala upon open-arms exploratory behaviors induced by ACPA in the central amygdala.

Four groups of animals received concurrent intra-central amygdala microinjection of subthreshold dose of GR127935 (5 µg/rat, intracental amygdala) or different doses of ACPA (0.00025, 0.0005, 0.001 and 0.002 µg/rat). Rats were tested in the EPM, 5 min after infusion. Treated groups were then retested in EPM, 24 h later, undrugged.

Results

Results from the experiment 1

Effects of the pretest intra-CeA microinjection of ACPA on the open-arms exploratory behaviors

Repeated measure and posthoc analysis between test and retest days showed that intra-BLA injection of ACPA at applied doses did not alter the transfer latency [Intra-groups: $F(1, 35) = 8.95$, $P < 0.01$, Inter-groups: $F(4, 35) = 1.63$, $P > 0.05$, Inter-Intra groups interaction: $F(4, 35) = 3.66$, $P > 0.05$; Fig. 1, panels 1A and 2A], %OAT [Intra-groups: $F(1, 35) = 15.09$, $P < 0.001$, Inter-groups: $F(4, 35) = 2.32$, $P > 0.05$, Inter-Intra groups interaction: $F(4, 35) = 4.31$, $P < 0.01$; Fig. 1, panels 1B and 2B], %OAE [Intra-

groups: $F(1, 35) = 32.40$, $P < 0.001$, Inter-groups: $F(4, 35) = 2.77$, $P > 0.05$, Inter-Intra groups interaction: $F(4, 35) = 8.45$, $P < 0.001$; Fig. 1, panels 1C and 2C] and locomotor activity [Intra-groups: $F(1, 35) = 0.24$, $P > 0.05$, Inter-groups: $F(4, 35) = 3.712$, $P > 0.05$, Inter-Intra groups interaction: $F(4, 35) = 497.4$, $P < 0.001$; Fig. 1, panels 1D and 2D] on test or retest days as compared to the own control groups, suggesting that ACPA applied doses does not appear to alter anxiety-like behaviors and aversive memory acquisition.

Results of the experiment 2

Effects of the pretest intra-CeA microinjection of CP94253 Hydrochloride on the open-arms exploratory behaviors

Repeated measure and posthoc analysis between test and retest days showed that intra-CeA injection of CP94253 HCL at applied doses did not alter the transfer latency [Intra-groups: $F(1, 35) = 32.68$, $P < 0.001$, Inter-groups: $F(4, 35) = 2.52$, $P > 0.05$, Inter-Intra groups interaction: $F(4, 35) = 1.405$, $P > 0.05$; Fig. 2, panels 1A and 2A], %OAT [Intra-groups: $F(1, 35) = 44.48$, $P < 0.001$, Inter-groups: $F(4, 35) = 9.57$, $P < 0.001$, Inter-Intra groups interaction: $F(4, 35) = 1.050$, $P > 0.05$; Fig. 2, panels 1B and 2B], %OAE [Intra-groups: $F(1, 35) = 15.58$, $P < 0.001$, Inter-groups: $F(4, 35) = 0.906$, $P > 0.05$, Inter-Intra groups interaction: $F(4, 35) = 1.45$, $P > 0.05$; Fig. 2, panels 1C and 2C] and locomotor activity [Intra-groups: $F(1, 35) = 6.78$, $P < 0.01$, Inter-groups: $F(4, 35) = 2.63$, $P > 0.05$, Inter-Intra groups interaction: $F(4, 35) = 1.68$, $P > 0.05$; Fig. 2, panels 1D and 2D] on test or retest days as compared to the own control groups, suggesting that reduced the emotional memory formation and locomotor activity but ineffective treatment on the anxiety-like behaviors.

Results of the experiment 3

The effects of the pretest intra-CeA microinjection of CP94253 HCL on the ACPA-induced open-arms exploratory behaviors

Two-way ANOVA and posthoc analysis showed that intra-CeA injection of the sub threshold dose CP94253 HCL decreased %OAT [Intra-groups: $F(1,$

70) = 0.18, $P > 0.05$, Inter-groups: $F(4, 70) = 3.63$, $P < 0.001$, Inter-Intra group interaction: $F(4, 70) = 1.009$, $P > 0.05$; Fig. 1, panels 1B and 3B] and %OAE [Intra-groups: $F(1, 70) = 0.869$, $P > 0.05$, Inter-groups: $F(4, 70) = 0.625$, $P > 0.05$, Inter-Intra group interaction: $F(4, 70) = 2.14$, $P < 0.01$; Fig. 1, panels 1C and 3C] while did not alter the transfer latency [Intra-groups: $F(1, 70) = 9.52$, $P < 0.01$, Inter-groups: $F(4, 70) = 0.76$, $P > 0.05$, Inter-Intra group interaction: $F(4, 70) = 0.98$, $P > 0.05$; Fig. 1, panels 1A and 3A] and locomotor activity [Intra-groups: $F(1, 70) = 23.82$, $P < 0.001$, Inter-groups: $F(4, 70) = 3.78$, $P < 0.01$, Inter-Intra group interaction: $F(4, 70) = 0.532$, $P > 0.05$; Fig. 1, panels 1D and 3D] already induced by ACPA on test day as compared to the respective control group, indicating that CP94253 HCL blocks the ACPA-induced anxiolytic-like behaviors. Moreover, two-way ANOVA indicated that the subthreshold dose CP94253 HCL decreased the transfer latency [Intra-groups: $F(1, 70) = 7.05$, $P < 0.01$, Inter-groups: $F(4, 70) = 2.58$, $P < 0.05$, Inter-Intra groups interaction: $F(4, 70) = 2.051$, $P > 0.05$; Fig. 1, panels 2A and 4A] and %OAT [Intra-groups: $F(1, 70) = 6.37$, $P < 0.05$, Inter-groups: $F(4, 70) = 4.17$, $P < 0.01$, Inter-Intra group interaction: $F(4, 70) = 17.92$, $P < 0.001$; Fig. 1, panels 2B and 4B] while did not alter %OAE [Intra-groups: $F(1, 70) = 2.164$, $P > 0.05$, Inter-groups: $F(4, 70) = 1.84$, $P > 0.05$, Inter-Intra group interaction: $F(4, 70) = 12.77$, $P < 0.001$; Fig. 1, panels 2C and 4C] and locomotor activity [Intra-groups: $F(1, 70) = 0.019$, $P > 0.05$, Inter-groups: $F(4, 70) = 2.813$, $P < 0.05$, Inter-Intra group interaction: $F(4, 70) = 2.925$, $P < 0.05$; Fig. 1, panels 2D and 4D] already induced by ACPA on retest day as compared to the respective control group. In conclusion, the data revealed that the intra-CeA injection of CP94253 HCL restored the ACPA-induced aversive memory deficits.

Results of the experiment 4

Effect of the pretest intra-CeA microinjection of GR127935 on the open-arms exploratory behaviors

The repeated measure and posthoc analysis showed that the intra-BLA injection of GR127935 increased transfer latency in retest day; Intra-groups: $F(1, 35) =$

35.36 , $P < 0.001$, Inter-groups: $F(4, 35) = 1.98$, $P > 0.05$, Inter-Intra group interaction: $F(4, 35) = 6.29$, $P < 0.001$; Fig. 2, panels 1A and 2A], %OAT in retest day; Intra-groups: $F(1, 35) = 39.33$, $P < 0.001$, Inter-groups: $F(4, 35) = 6.288$, $P < 0.001$, Inter-Intra group interaction: $F(4, 35) = 0.47$, $P > 0.05$; Fig. 2, panels 1B and 2B], %OAE in retest day; Intra-groups: $F(1, 35) = 33.90$, $P < 0.001$, Inter-groups: $F(4, 35) = 4.24$, $P < 0.01$, Inter-Intra group interaction: $F(4, 35) = 2.14$, $P < 0.05$; Fig. 2, panels 1C and 2CA], while alter locomotor activity [Intra-groups: $F(1, 35) = 6.56$, $P < 0.05$, Inter-groups: $F(4, 35) = 2.64$, $P < 0.05$, Inter-Intra groups interaction: $F(4, 35) = 2.87$, $P < 0.05$; Fig. 2, panels 1D and 2D].

Results of the experiment 5

The effects of the pretest intra-CeA microinjection of GR127935 on the ACPA-induced open-arms exploratory behaviors

Two-way ANOVA and post hoc analysis showed that the intra-CeA injection of the sub threshold dose GR127935 did not alter the exploratory behaviors already induced by the sub threshold and effective doses of ACPA both on test and retest days when compared to the respective controls. The measured indices for compared to test days were transfer latency [Intra-groups: $F(1, 70) = 6.53$, $P < 0.05$, Inter-groups: $F(4, 70) = 2.14$, $P > 0.05$, Inter-Intra groups interaction: $F(4, 70) = 3.069$, $P < 0.05$; Fig. 1, panels 1A and 5A], %OAT [Intra-groups: $F(1, 70) = 0.009$, $P > 0.05$, Inter-groups: $F(4, 70) = 9.565$, $P < 0.001$, Inter-Intra group interaction: $F(3, 56) = 3.1$, $P > 0.05$; Fig. 3, panels 1B and 5B], %OAE [Intra-groups: $F(1, 70) = 5.32$, $P < 0.05$, Inter-groups: $F(4, 70) = 2.38$, $P > 0.05$, Inter-Intra group interaction: $F(4, 47) = 2.47$, $P > 0.05$; Fig. 1, panels 1C and 5C] and locomotor activity [Intra-groups: $F(1, 70) = 14.98$, $P < 0.001$, Inter-groups: $F(4, 70) = 3.21$, $P < 0.01$, Inter-Intra groups interaction: $F(4, 70) = 3.13$, $P > 0.05$; Fig. 1, panels 1D and 5D]. The measured indices for compared of retest days were transfer latency [Intra-groups: $F(1, 70) = 1.47$, $P > 0.05$, Inter-groups: $F(4, 70) = 0.65$, $P > 0.05$, Inter-Intra groups interaction: $F(4, 70) = 4.18$, $P < 0.01$; Fig. 1, panels 2A and 6A], %OAT [Intra-groups: $F(1, 70) = 0.22$, $P >$

0.05, Inter-groups: $F(4, 70) = 0.324$, $P > 0.05$, Inter-Intra groups interaction: $F(4, 70) = 4.461$, $P < 0.001$; Fig. 1, panels 2B and 6B], %OAE [Intra-groups: $F(1, 70) = 0.068$, $P > 0.05$, Inter-groups: $F(4, 70) = 0.072$, $P > 0.05$, Inter-Intra groups interaction: $F(4, 70) = 11.23$, $P < 0.001$; Fig. 1, panels 2C and 6C] and locomotor activity [Intra-groups: $F(1, 70) = 0.59$, $P > 0.05$, Inter-groups: $F(4, 70) = 0.406$, $P > 0.05$, Inter-Intra groups interaction: $F(4, 70) = 3.64$, $P < 0.01$; Fig. 1, panels 2D and 6D]. In conclusion, our data suggested that the intra-CeA injection of GR127935 does not alter the ACPA-induced exploratory behaviors upon EPM test and retest.

Histology

Fig. 1 shows locations of the injection cannulae tips in the central amygdala. Illustrate the representative sections taken from the rat's brain atlas of Paxinos and Watson [44]. Shaded and dark areas represent the approximate points in which the cannulae were positioned for each animal. Data from the animals with injection sites located outside the central amygdala were not used in the analysis.

Discussion

The effects of ACPA on anxiety like behaviors and learning

The obtained results of the present study indicated that the pretest injections of various concentrations of ACPA, the selective agonist of the CB1 receptor, into the central amygdala led to the amnesia, while were ineffective on anxiety related behaviors. By receiving signals from basolateral amygdala, central amygdala nucleus which is the critical region implicated in learning and anxiety process, sent messages to targets, including hypothalamus and brain stem, the area involved in the most autonomic and electrophysiological behaviors caused by fear, anxiety and emotional learning (Walker *et al.*, 2003). Based on the behavioral studies, the anxiety like behaviors have been mentioned as one of the main effects of cannabinoids in animal and human models (Lichtman *et al.*, 2002; Zarrindast *et al.*, 2010).

The anxiolytic impacts of agonists of CB1 receptors

have been supported by the induced changes by the applications of Win 55,229 (Haller *et al.*, 2007) and CP55,940 [55, 56], in contrast to antagonists of CB1, such as AM251 (Haller *et al.*, 2002; Rodrigues *et al.*, 2004). Δ^9 -THC, a non selective cannabinoid agonist, and anandamide, an endogenous cannabinoid ligand, elevated the presence of mice in the close arm, indicator of anxiogenic effects, which are in consistent with our finding. Moreover, there are some reports reflecting the cannabinoid agonists led to the anxiety response (Zarrindast *et al.*, 2008; Zarrindast *et al.*, 2010). In addition, the consumption of cannabinoid drugs in human caused the anxiety reaction (Hall *et al.*, 1998). It has been stated that the animal responses to cannabinoids (McGregor IS *et al.*, 1996) and the diffusions of the cannabinoid receptors in the brain structure are variable dependent to the species (Arnold *et al.*, 2001).

Cannabinoid antagonist reverses the various anxiety related behaviors induced by Cannabis sativa (Hall *et al.*, 1998). Overall, it seems that the dose of cannabinoid agonist and experimental animal species play critical roles in anxiety related responses caused by cannabinoids.

The recorded findings from the current study clearly reflected that ACPA damaged memory. Based on the various behavioral studies, the destructions in short term memory and spatial learning have been proposed as the main effects of cannabinoids (Moshfegh *et al.*, 2010; Nasehi *et al.*, 2010). The firing of amygdala neurons during formation of short term memory were inhibited by Cannabinoids (Wilson *et al.*, 2002; Wilson *et al.*, 2002; Moore *et al.*, 2010). The systemic pretest usage of Delta-9-Tetrahydrocannabinol ruined working memory while restored (Nava *et al.*, 2000; Lopez-Moreno *et al.*, 2008) and improved memory process by antagonist of CB1 receptor (Da and Takahashi, 2000).

Also, there are evidences indicating agonist of CB1 receptor may affect achievement and/or fixation of memory (Da and Takahashi, 2000; Robinson *et al.*, 2007). The high rate of CB1 receptors in the area, like

amygdale and the implication of cannabinoid system of amygdala in memory process have been confirmed by different researches (Viveros *et al.*, 2005; Collin *et al.*, 2007; Marco *et al.*, 2009). The modulating role of the cannabinoid system in the memory consolidation process has been proposed (BRUSCO 2008) and

seems that the mentioned system may act as a dual neuromodulator (Moreira *et al.*, 2008). The reductions in release of glutamate and acetyl colin in amygdala and some other related regions, including hippocamp could be responsible for destroying the memory.




Fig. 1. (panels 1 and 2) shows open-arms exploratory behaviors following N the pretest intraperitoneal injection of ACPA. After 24 h, all groups were retested in the EPM, undrugged. %Open-Arms Time (A); %Open-Arms Entries (B) and number of Closed Arm Entries (C). Values are expressed as mean \pm S.E.M (n = 8 in each group). *P < 0.05 and **P < 0.01 different from saline group in panel 1. P < 0.01 and P < 0.001 different from the respective saline group in panel 1. + < 0.05 and ++ < 0.01 different from the saline group in panel 2. In addition, Fig. 1 (panels 3 and 4 for CP94253 HCL, while panels 5 and 6 for GR127935) shows the effect of the intra-CeA pre-test injection of the subthreshold dose CP94253 HCL and GR127935 on open-arms exploratory-like behaviors induced by both the subthreshold and effective doses of ACPA. After 24 h, all groups were retested in the EPM, undrugged. Values are expressed as mean \pm S.E.M (n = 8 in each group). For panels 3 and 4, δ < 0.05 as compared to the respective group in panel 1 (comparison of the two drugs on test day), while β < 0.05 is as compared to the respective group in panel 2 (comparison of the two drugs on retest day).

Effect of intra-CeA microinjection of agonist and antagonist of 5HT₁ receptor on anxiety behaviors and memory

Intra-CeA microinjection of CP Hcl and GR (respectively agonist and antagonist of 5HT_{1B} serotonin receptor) at high concentrations, immediately pretest, were ineffective on the anxiety

however, led to amnesia. The highest levels of 5HT_{1A}, _B receptors have been recorded in hippocamp, septom, cortex and amygdala, locations of post synaptic receptors (Davis and Claridge, 1998).

Conditional fear studies revealed that 5HT inhibited the inducing signals to the amygdala nucleus

reflecting the critical involvement of amygdala in Conditional fear reaction (LeDoux, 1998; Armony *et al.*, 1998). Analysis of the found data of this study showed that anxiety like behaviors were not influenced by agonist or antagonist of 5HT_{1B}. These results are contradictory to the findings of Dimmler

2004 and Ramboz 1998 shown that the various types of 5HT₁ agonists mediated the anxiogenic effects in animal and human models. Also, it has been stated that 5HT_{1A} agonist acts as an anxiolytic compound in animals and human model systems (Ramboz *et al.*, 1998; El-Khodori *et al.*, 2004).




Fig. 2. Open-arms exploratory behaviors following the pretest intra-CeA microinjections of CP94253 (panels 1 and 2) and GR127935 (panels 3 and 4). After 24 h, all groups were retested in the EPM, undrugged. %Open-ArmsTime (A); %Open-Arms Entries (B) and number of Closed Arm Entries (C). Values are expressed as mean \pm S.E.M ($n = 8$ in each group). * $P < 0.05$ and ** $P < 0.01$ different from the respective saline group in panel 1. + $P < 0.05$ and ++ $P < 0.051$ different from the control saline group in panel 3. $\beta P < 0.05$ and $\beta\beta P < 0.01$ different from the respective saline group in panel 4.

The complete depletion of 5HT₁ receptors led to the anxiety like behaviors (Gross *et al.*, 2002). The anxiolytic impacts of serotonin have been well documented and there are more concerns about 5HT₁ receptors for improving the anxiety related disorders (Laaris *et al.*, 1997; Belzung *et al.*, 2001; Menard *et al.*, 2007). There is a positive correlation between 5HT concentrations in brain and anxiety rate (Nasehi *et al.*, 2010). 5HT plays a vital role in the development and continuity of anxiety disorders (Zarrindast *et al.*, 2008). The concentrations of 5HT in brain of different mouse and rat species were variable and there were close relation between 5HT contents in central neurone system (CNS) and anxiety related behaviors (Zarrindast *et al.*, 2008). The

increases in 5HT levels in various regions of CNS have been recorded in animals showing the anxiety behaviors (Gomez-Merino *et al.*, 2001; Kusserow *et al.*, 2004). According to the obtained results from the present study it could be stated that the high fear enhances the concentrations of 5HT in serotonergic area and there is a correlation between 5HT levels and anxiety in animals.

In this study, the recorded destruction of memory caused by injection of agonist of 5HT₁ receptor is in agreement with findings of Luttgen (Luttgen *et al.*, 2005). The disturbance in the learning process induced by the different doses of 8-OHPAT, agonist of 5HT_{1A} receptor, in PA and water Maze tests have

been reported (Carli *et al.*, 1999; Luttgen *et al.*, 2005). In the current research, the antagonist of 5HT_{1B} did not influence memory process which inconsistency with the results of Madjid (Madjid *et al.*, 2006) and Luttgen (Luttgen *et al.*, 2005) reflecting the improving impacts of 5HT_{1A} antagonist on the learning process under the various kinds of tests, including EPM, PA and MAZE tests. It has been shown by the different studies that 5HT₁ antagonist affects spatial memory via the hippocamp and amygdala as well as the activity of 5HT₁ receptor may indirectly involve in the mechanisms of strategical and spatial learning (Horisawa *et al.*, 2011).

The interaction of serotonin and cannabinoid receptors on anxiety behaviors and memory

Based on the obtained results from the present study, the simultaneous injections of different doses of ACPA and ineffective dose of serotonin agonist were ineffective treatments on anxiety like behaviors, in contrast to ineffective dose of serotonin antagonist which had the anxiolytic effects. During retest the destruction of memory achievement caused by ACPA restored by the injection of the ineffective dose of this drug. Based the evaluations done on the serotonin and the cannabinoid system in the amygdala, the both CB₁ and 5HT_{1A} are the ligand dependent channels and the activation of CB₁ receptor may influence the stimulation of raphe nuclei by the control of stimulating and inhibitory inputs or by direct inhibiting of serotonergic neurons (Hermann *et al.*, 2002; Haj-Dahmane and Shen., 2011). The both cannabinoid and serotonin receptors are present in gabargic neurons of amygdala and hippocamp structures (Akimova *et al.*, 2009). There is an interaction between cannabinoid and serotonergic systems in neuronal transmissions. The both CB₁ receptors and serotonin transporter protein are located in rat amygdala (Kleijn *et al.*, 2011). CB₁ receptors presented on the serotonergic fibers of raphe nucleus forms synaps in amygdala; therefore it has been concluded that there is an interaction between cannabinoid and serotonergic systems (Brailov *et al.*, 2000).

The activation of the CB₁ receptor decreased Ca²⁺-dependent release of serotonin from the frontal cortical terminals of the mouse (Darmani and Pandya, 2000; Yang *et al.*, 2010). Cannabinoid presynapsis CB₁ receptors prevent the secretion of the many neurotransmitters, including γ -aminobutyric acid (GABA), glutamate, dopamine, noradrenaline, acetylcholin and 5- hydroxytryptamine (5-HT). The reduction in 5HT secretion by the activation of cannabinoid CB₁ have been confirmed by the functional electrophysiological studies in neocortex (Nakazi *et al.*, 2000) and it seems that this decrease possesses the considerable inhibitory effects. In the current research serotonin agonist partially alleviated anxiolytic impacts of ACPA, but it was not significant. Also the destroying impacts of ACPA on the memory process were restored by the agonist and antagonist of serotonin. It could be explained by the substitution of ACPA-prevented neurotransmitters by serotonin agonist. The damaging effects of ACPA on the learning and memory could be attributed to the presynapsis inhibition of serotonin release by the cannabinoid receptors.

Acknowledgment

This study was supported by Islamic Azad University, Science and Research Branch Branch. Authors would like to thank Dr M. Nasehi for his warming and professional helps.

References

- Akimova E, Lanzenberger R, Kasper S.** 2009. The serotonin-1A receptor in anxiety disorders. *Biological Psychiatry* **66**, 627-35.
<http://dx.doi.org/10.1016/j.biopsych.2009.03.012>
- Armony JL, Quirk GJ, LeDoux JE.** 1998. Differential effects of amygdala lesions on early and late plastic components of auditory cortex spike trains during fear conditioning. *The Journal of Neuroscience* **18**, 2592-601.
- Arnold JC, Topple AN, Mallet PE, Hunt GE, McGregor IS.** 2001. The distribution of cannabinoid-induced Fos expression in rat brain:

differences between the Lewis and Wistar strain. *Brain Research* **921**, 240-55.

[http://dx.doi.org/10.1016/S0006-8993\(01\)03127-4](http://dx.doi.org/10.1016/S0006-8993(01)03127-4)

Baxter MG, Murray EA. 2002. The amygdala and reward. *Natural Reviews Neuroscience* **3**, 563-73.

<http://dx.doi.org/10.1038/nrn875>

Begg M, Pacher P, Batkai S, Osei-Hyiaman D, Offertaler L, Mo FM, Liu J, Kunos G. 2005. Evidence for novel cannabinoid receptors. *Pharmacology & Therapeutics* **106**, 133-45.

<http://dx.doi.org/10.1016/j.pharmthera.2004.11.005>

Belzung C. 2001. The genetic basis of the pharmacological effects of anxiolytics: a review based on rodent models. *Behavioral Pharmacology* **12**, 451-60.

<http://dx.doi.org/10.1097/00008877-200111000-00005>

Brailov I, Bancila M, Brisorgueil MJ, Miquel MC, Hamon M, Verge D. 2000. Localization of 5-HT(6) receptors at the plasma membrane of neuronal cilia in the rat brain. *Brain Research* **872**, 271-5.

[http://dx.doi.org/10.1016/S0006-8993\(00\)02519-1](http://dx.doi.org/10.1016/S0006-8993(00)02519-1)

Bruss M, Eucker T, Gothert M, Bonisch H. 2000. Exon-intron organization of the human 5-HT_{3A} receptor gene. *Neuropharmacology* **39**, 308-15.

[http://dx.doi.org/10.1016/S0028-3908\(99\)00116-1](http://dx.doi.org/10.1016/S0028-3908(99)00116-1)

Carli M, Silva S, Balducci C, Samanin R. 1999. WAY 100635, a 5-HT_{1A} receptor antagonist, prevents the impairment of spatial learning caused by blockade of hippocampal NMDA receptors. *Neuropharmacology* **38**, 1165-73.

[http://dx.doi.org/10.1016/S0028-3908\(99\)00038-6](http://dx.doi.org/10.1016/S0028-3908(99)00038-6)

Carvalho MC, Albrechet-Souza L, Masson S, Brandao ML. 2005. Changes in the biogenic amine content of the prefrontal cortex, amygdala, dorsal hippocampus, and nucleus accumbens of rats submitted to single and repeated sessions of the

elevated plus-maze test. *Brazilian Journal of Medical and Biological Research* **38**, 1857-66.

<http://dx.doi.org/10.1590/S0100879X2005001200014>

Casswell S, Marks DF. 1973. Cannabis and temporal disintegration in experienced and naive subjects. *Science* **179**, 803-5.

<http://dx.doi.org/10.1126/science.179.4075.803>

Casarrubea M, Sorbera F, Crescimanno G. 2009. Structure of rat behavior in hole-board: I) multivariate analysis of response to anxiety. *Physiology & Behavior* **96**, 174-9.

<http://dx.doi.org/10.1016/j.physbeh.2008.09.025>

Chegin HR, Nasehi M, Zarrindast MR. 2014. Differential role of the basolateral amygdala 5-HT₃ and 5-HT₄ serotonin receptors upon ACPA-induced anxiolytic-like behaviors and emotional memory deficit in mice. *Behavioural Brain Research* **261**, 114-26.

<http://dx.doi.org/10.1016/j.bbr.2013.12.007>

Collin C, Davies P, Mutiboko IK, Ratcliffe S. 2007. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. *European Journal of Neurology* **14**, 290-6.

<http://dx.doi.org/10.1111/j.1468-1331.2006.01639.x>

Cruz-Morales SE, Santos NR, Brandao ML. 2002. One-trial tolerance to midazolam is due to enhancement of fear and reduction of anxiolytic-sensitive behaviors in the elevated plus-maze retest in the rat. *Pharmacology Biochemistry and Behavior* **72**, 973-8.

[http://dx.doi.org/10.1016/S0091-3057\(02\)00813-4](http://dx.doi.org/10.1016/S0091-3057(02)00813-4)

Da S, Takahashi RN. 2002. SR 141716A prevents delta 9-tetrahydrocannabinol-induced spatial learning deficit in a Morris-type water maze in mice. *Progress in Neuro-Psychopharmacology & Biological Psychiatry* **26**, 321-5.

[http://dx.doi.org/10.1016/S0278-5846\(01\)00275-5](http://dx.doi.org/10.1016/S0278-5846(01)00275-5)

Darmani NA, Pandya DK. 2000. Involvement of other neurotransmitters in behaviors induced by the cannabinoid CB1 receptor antagonist SR 141716A in naive mice. *Journal of Neural Transmission* **107**, 931-45.

<http://dx.doi.org/10.1007/s007020070043>

Davis C, Claridge G. 1998. The eating disorders as addiction: a psychobiological perspective. *Addictive Behaviors* **23**, 463-75.

[http://dx.doi.org/10.1016/S0306-4603\(98\)00009-4](http://dx.doi.org/10.1016/S0306-4603(98)00009-4)

Davis M. 2006. Neural systems involved in fear and anxiety measured with fear-potentiated startle. *American Psychologist* **61**, 741-56.

<http://dx.doi.org/10.1037/0003-066X.61.8.741>

Degroot A, Salhoff C, Davis RJ, Nomikos GG. 2005. Genetic deletion of CB1 receptors improves non-associative learning. *Behavioural Brain Research* **162**, 161-4.

<http://dx.doi.org/10.1016/j.bbr.2005.02.018>

De Oliveira Alvares L, de Oliveira LF, Camboimm C, Diehl F, Genro BP, Lanziotti VB, Quillfeldt JA. 2005. Amnestic effect of intrahippocampal AM251, a CB1-selective blocker, in the inhibitory avoidance, but not in the open field habituation task, in rats. *Neurobiology of Learning and Memory* **83**, 119-24.

<http://dx.doi.org/10.1016/j.nlm.2004.10.002>

El-Khodori BF, Dimmler MH, Amara DA, Hofer M, Hen R, Brunner D. 2004. Juvenile 5HT(1B) receptor knockout mice exhibit reduced pharmacological sensitivity to 5HT(1A) receptor activation. *International Journal of Developmental Neuroscience* **22**, 405-13.

<http://dx.doi.org/10.1016/j.ijdevneu.2004.06.001>

Eslimi D, Oryan S, Nasehi M, Zarrindast MR. 2011. Effects of opioidergic systems upon anxiolytic-like behaviors induced in cholestatic rats. *European Journal of Pharmacology* **670**, 180-5.

<http://dx.doi.org/10.1016/j.ejphar.2011.08.024>

File SE. 1993. The interplay of learning and anxiety in the elevated plus-maze. *Behavioural Brain Research* **58**, 199-202.

[http://dx.doi.org/10.1016/0166-4328\(93\)90103-W](http://dx.doi.org/10.1016/0166-4328(93)90103-W)

Ghiasvand M, Rezayof A, Ahmadi S, Zarrindast MR. 2009. 2 beta1-noradrenergic system of the central amygdala is involved in state-dependent memory induced by a cannabinoid agonist, WIN55,212-2, in rat. *Behavioural Brain Research* **225**, 1-6.

<http://dx.doi.org/10.1016/j.neuroscience.2012.04.008>

Ghiasvand M, Rezayof A, Zarrindast M R, Ahmadi S. 2011. Activation of cannabinoid CB1 receptors in the central amygdala impairs inhibitory avoidance memory consolidation via NMDA receptors. *Neurobiology of Learning and Memory* **96**, 333-8.

<http://dx.doi.org/10.1016/j.nlm.2011.06.008>

Ghizoni DM, Joao LM, Moratelli Neto L, da Cunha IC, Orlandi Pereira L, Borges FR, Battisti R, de Oliveira LG, Meneghini L, Lucinda AM, Marino Neto J, Paschoalini MA, Faria MS. 2006. The effects of metabolic stress and vagotomy on emotional learning in an animal model of anxiety. *Neurobiology of Learning and Memory* **86**, 107-16.

<http://dx.doi.org/10.1016/j.nlm.2006.01.005>

Gianlorenco AC, Canto-de-Souza A, Mattioli R. 2011. Microinjection of histamine into the cerebellar vermis impairs emotional memory consolidation in mice. *Brain Research Bulletin* **86**, 134-8.

<http://dx.doi.org/10.1016/j.brainresbull.2011.05.014>

Gomez-Merino D, Bequet F, Berthelot M, Chennaoui M, Guezennec CY. 2001. Site-dependent effects of an acute intensive exercise on extracellular 5-HT and 5-HIAA levels in rat brain. *Neuroscience Letters* **301**, 143-6.

[http://dx.doi.org/10.1016/S0304-3940\(01\)01626-3](http://dx.doi.org/10.1016/S0304-3940(01)01626-3)

Gross C, Zhuang X, Stark K, Ramboz S, Oosting R, Kirby L, Santarelli L, Beck S, Hen R. 2002. Serotonin_{1A} receptor acts during development to establish normal anxiety-like behaviour in the adult. *Nature* **416**, 396-400.

<http://dx.doi.org/10.1038/416396a>

Hall W, Solowij N. 1998. Adverse effects of cannabis. *Lancet* **352**, 1611-6.

[http://dx.doi.org/10.1016/S0140-6736\(98\)05021-1](http://dx.doi.org/10.1016/S0140-6736(98)05021-1)

Haj-Dahmane S, Shen RY. 2011. Modulation of the serotonin system by endocannabinoid signaling. *Neuropharmacology* **61**, 414-20.

<http://dx.doi.org/10.1016/j.neuropharm.2011.02.016>

Hajos N, Freund TF. 2002. Pharmacological separation of cannabinoid sensitive receptors on hippocampal excitatory and inhibitory fibers. *Neuropharmacology* **43**, 503-10.

[http://dx.doi.org/10.1016/S0028-3908\(02\)00157-0](http://dx.doi.org/10.1016/S0028-3908(02)00157-0)

Haller J, Bakos N, Rodriguiz RM, Caron MG, Wetsel WC, Liposits Z. 2002. Behavioral responses to social stress in noradrenaline transporter knockout mice: effects on social behavior and depression. *Brain Research Bulletin* **58**, 279-84.

[http://dx.doi.org/10.1016/S0361-9230\(02\)00789-X](http://dx.doi.org/10.1016/S0361-9230(02)00789-X)

Haller J, Bakos N, Szirmay M, Ledent C, Freund TF. 2002. The effects of genetic and pharmacological blockade of the CB₁ cannabinoid receptor on anxiety. *European Journal of Neuroscience* **16**, 1395-8.

<http://dx.doi.org/10.1046/j.1460-9568.2002.02192.x>

Haller J, Matyas F, Soproni K, Varga B, Barsy B, Nemeth B, Mikics E, Freund TF, Hajos N. 2007. Correlated species differences in the effects of cannabinoid ligands on anxiety and on GABAergic and glutamatergic synaptic transmission. *European Journal of Neuroscience* **25**, 2445-56.

<http://dx.doi.org/10.1111/j.1460-9568.2007.05476.x>

Heimer L, Van Hoesen GW. 2006. The limbic

lobe and its output channels: implications for emotional functions and adaptive behavior. *Neuroscience & Biobehavioral Reviews* **30**, 126-47.

<http://dx.doi.org/10.1016/j.neubiorev.2005.06.006>

Hermann H, Marsicano G, Lutz B. 2002. Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain. *Neuroscience* **109**, 451-60.

[http://dx.doi.org/10.1016/S0306-4522\(01\)00509-7](http://dx.doi.org/10.1016/S0306-4522(01)00509-7)

Horisawa T, Ishibashi T, Nishikawa H, Enomoto T, Toma S, Ishiyama T, Taiji M. 2011. The effects of selective antagonists of serotonin 5-HT₇ and 5-HT_{1A} receptors on MK-801-induced impairment of learning and memory in the passive avoidance and Morris water maze tests in rats: mechanistic implications for the beneficial effects of the novel atypical antipsychotic lurasidone. *Behavioral Brain Research* **220**, 83-90.

<http://dx.doi.org/10.1016/j.bbr.2011.01.034>

Jafari MR, Golmohammadi S, Ghiasvand F, Zarrindast M R, Djahanguiri B. 2007. Influence of nicotinic receptor modulators on CB₂ cannabinoid receptor agonist (JWH133)-induced antinociception in mice. *Behavioral Pharmacology* **18**, 691-7.

<http://dx.doi.org/10.1097/FBP.0b013e3282f00c10>

Kleijn J, Cremers TI, Hofland CM, Westerink BH. 2011. CB-1 receptors modulate the effect of the selective serotonin reuptake inhibitor, citalopram on extracellular serotonin levels in the rat prefrontal cortex. *Neuroscience Research* **70**, 7-334.

<http://dx.doi.org/10.1016/j.neures.2011.03.004>

Kusserow H, Davies B, Hortnagl H, Voigt I, Stroh T, Bert B, Deng DR, Fink H, Veh RW, Theuring F. 2004. Reduced anxiety-related behaviour in transgenic mice overexpressing serotonin 1A receptors. *Molecular Brain Research* **129**, 104-16.

<http://dx.doi.org/10.1055/s-2003-825531>

- Lam DD, Garfield A S, Marston OJ, Shaw J, Heisler LK.** 2010. Brain serotonin system in the coordination of food intake and body weight. *Pharmacology Biochemistry and Behavior* **97**, 84-91.
<http://dx.doi.org/10.1016/j.pbb.2010.09.003>
- Laaris N, Le Poul E, Hamon M, Lanfumey L.** 1997. Stress-induced alterations of somatodendritic 5-HT_{1A} autoreceptor sensitivity in the rat dorsal raphe nucleus-in vitro electrophysiological evidence. *Fundamental and Clinical Pharmacology* **11**, 206-14.
<http://dx.doi.org/10.1111/j.14728206.1997.tb00187.x>
- LeDoux J.** 1998. Fear and the brain: where have we been, and where are we going? *Biological Psychiatry* **44**, 1229-38.
[http://dx.doi.org/10.1016/S0006-3223\(98\)00282-0](http://dx.doi.org/10.1016/S0006-3223(98)00282-0)
- Lee EJ, Son GH, Chung S, Lee S, Kim J, Choi S, Kim K.** 2011. Impairment of fear memory consolidation in maternally stressed male mouse offspring: evidence for nongenomic glucocorticoid action on the amygdala. *Journal of Neuroscience* **31**, 7131-40.
<http://dx.doi.org/10.1523/JNEUROSCI.4692-10.2011>
- Lichtman AH, Varvel SA, Martin BR.** 2002. Endocannabinoids in cognition and dependence. *Prostaglandins Leukot Essent Fatty Acids* **66**, 269-85.
<http://dx.doi.org/10.1054/plef.2001.0351>
- Lichtman AH.** 2000. SR 141716A enhances spatial memory as assessed in a radial-arm maze task in rats. *European Journal of Pharmacology* **404**, 175-9.
[http://dx.doi.org/10.1016/S0014-2999\(00\)00615-4](http://dx.doi.org/10.1016/S0014-2999(00)00615-4)
- Lopez-Moreno JA, Gonzalez-Cuevas G, Moreno G, Navarro M.** 2008. The pharmacology of the endocannabinoid system: functional and structural interactions with other neurotransmitter systems and their repercussions in behavioral addiction. *Addiction Biology* **13**, 160-87.
<http://dx.doi.org/10.1111/j.1369-1600.2008.00105.x>
- Luttgen M, Elvander E, Madjid N, Ogren SO.** 2005. Analysis of the role of 5-HT_{1A} receptors in spatial and aversive learning in the rat. *Neuropharmacology* **48**, 830-52.
<http://dx.doi.org/10.1016/j.neuropharm.2005.01.007>
- Luttgen M, Ogren SO, Meister B.** 2005. 5-HT_{1A} receptor mRNA and immunoreactivity in the rat medial septum/diagonal band of Broca-relationships to GABAergic and cholinergic neurons. *Journal of Chemical Neuroanatomy* **29**, 93-111.
<http://dx.doi.org/10.1016/j.jchemneu.2004.09.001>
- Madjid N, Tottie EE, Luttgen M, Meister B, Sandin J, Kuzmin A, Stiedl O, Ogren SO.** 2006. 5-Hydroxytryptamine 1A receptor blockade facilitates aversive learning in mice: interactions with cholinergic and glutamatergic mechanisms. *Journal of Pharmacology and Experimental Therapeutics* **316**, 581-91.
<http://dx.doi.org/10.1124/jpet.105.092262>
- Marco EM, Viveros MP.** 2009. The critical role of the endocannabinoid system in emotional homeostasis: avoiding excess and deficiencies. *Mini Reviews in Medicinal Chemistry* **9**, 1407-15.
<http://dx.doi.org/10.2174/138955709789957468>
- Marco EM, Viveros MP.** 2009. [Functional role of the endocannabinoid system in emotional homeostasis]. *Review of neurology* **48**, 20-6.
- McGregor IS, Dastur FN, McLellan RA, Brown RE.** 1996. Cannabinoid modulation of rat pup ultrasonic vocalizations. *European Journal of Pharmacology* **313**, 43-9.
[http://dx.doi.org/10.1016/0014-2999\(96\)00511-0](http://dx.doi.org/10.1016/0014-2999(96)00511-0)
- Menard G, Turmel V, Bissonnette EY.** 2007. Serotonin modulates the cytokine network in the lung: involvement of prostaglandin E₂. *Clinical & Experimental Immunology* **150**, 340-8.
<http://dx.doi.org/10.1111/j.1365-2249.2007.03492.x>
- Miquel MC, Emerit MB, Gingrich JA, Nosjean**

A, Hamon M, Mestikawy S. 1995. Developmental changes in the differential expression of two serotonin 5-HT₃ receptor splice variants in the rat. *Journal of Neurochemistry* **65**, 475-83.

<http://dx.doi.org/10.1046/j.14714159.1995.65020475.x>

Moreira FA, Lutz B. 2008. The endocannabinoid system: emotion, learning and addiction. *Addiction Biology* **13**, 19-212.

<http://dx.doi.org/10.1111/j.1369-1600.2008.00104.x>

Moshfegh A, Babaei P, Oryan S, Soltani B, Zarrindast MR. 2010. Involvement of dorsal hippocampal alpha1-adrenergic receptors in the effect of WIN55, 212-2 on memory retrieval in inhibitory avoidance task. *Neuroscience Letters* **489**, 69-73.

<http://dx.doi.org/10.1016/j.neulet.2010.07.079>

Moore NL, Greenleaf AL, Acheson SK, Wilson WA, Swartzwelder HS, Kuhn CM. 2010. Role of cannabinoid receptor type 1 desensitization in greater tetrahydrocannabinol impairment of memory in adolescent rats. *Journal of Pharmacology and Experimental Therapeutics* **335**, 294-301.

<http://dx.doi.org/10.1124/jpet.110.169359>

Motevasseli T, Rezayof A, Zarrindast MR, Nayer-Nouri T. 2010. Role of ventral hippocampal NMDA receptors in anxiolytic-like effect of morphine. *Physiological Behaviors* **101**, 608-13.

<http://dx.doi.org/10.1016/j.physbeh.2010.09.013>

Nakazi M, Bauer U, Nickel T, Kathmann M, Schlicker E. 2000. Inhibition of serotonin release in the mouse brain via presynaptic cannabinoid CB₁ receptors. *Naunyn-Schmiedeberg's Archives of Pharmacology* **361**, 19-24.

<http://dx.doi.org/10.1007/s002109900147>

Nasehi M, Piri M, Nouri M, Farzin D, Nayer-Nouri T, Zarrindast MR. 2010. Involvement of dopamine D₁/D₂ receptors on harmaline-induced amnesia in the step-down passive avoidance test. *European Journal of Pharmacology* **634**, 77-83.

<http://dx.doi.org/10.1177/0269881111421972>

Nasehi M, Piri M, Jamali-Raeufy N, Zarrindast MR. 2010. Influence of intracerebral administration of NO agents in dorsal hippocampus (CA1) on cannabinoid state-dependent memory in the step-down passive avoidance test. *Physiology & Behavior* **100**, 297-304.

<http://dx.doi.org/10.1016/j.physbeh.2010.02.025>

Nava F, Carta G, Battasi AM, Gessa GL. 2000. D(2) dopamine receptors enable delta(9)-tetrahydrocannabinol induced memory impairment and reduction of hippocampal extracellular acetylcholine concentration. *British Journal of Pharmacology* **130**, 1201-10

<http://dx.doi.org/10.1038/sj.bjp.0703413>

Nikseresht S, Etebary S, Karimian M, Nabavizadeh F, Zarrindast MR, Sadeghipour HR. 2012. Acute administration of Zn, Mg, and thiamine improves postpartum depression conditions in mice. *Archives of Iranian Medicine* **15**, 306-11.

Nutt CL, Zerillo CA, Kelly GM, Hockfield S. 2001. Brain enriched hyaluronan binding (BEHAB)/brevican increases aggressiveness of CNS-1 gliomas in Lewis rats. *Cancer Research* **61**, 7056-9.

Onaivi ES, Green MR, Martin BR. 1990. Pharmacological characterization of cannabinoids in the elevated plus maze. *Journal of Pharmacology and Experimental Therapeutics* **253**, 1002-9.

Pacher P, Batkai S, Kunos G. 2006. The endocannabinoid system as an emerging target of pharmacotherapy. *Pharmacological Reviews* **58**, 389-462.

<http://dx.doi.org/10.1124/pr.58.3.2>

Paxinos G, Watson C. 2007. *The Rat Brain in Stereotaxic Coordinates* (6rd ed.). Academic Press, London.UK.

Pellow S. 1986. Anxiolytic and anxiogenic drug

effects in a novel test of anxiety: are exploratory models of anxiety in rodents valid? *Methods and Findings in Experimental and Clinical Pharmacology* **8**, 557-65.

Ramboz S, Oosting R, Amara DA, Kung HF, Blier P, Mendelsohn M, Mann JJ, Brunner D, Hen R. 1998. Serotonin receptor 1A knockout: an animal model of anxiety-related disorder. *Proceedings of the National Academy of Sciences of the United States of America* **95**, 14476-81.
<http://dx.doi.org/10.1073/pnas.95.24.14476>

Rezayof A, Golhasani-Keshtan F, Haeri-Rohani A, Zarrindast MR. 2007. Morphine-induced place preference: involvement of the central amygdala NMDA receptors. *Brain Research* **1133**, 34-41.
<http://dx.doi.org/10.1016/j.brainres.2006.11.049>

Rezayof A, Habibi P, Zarrindast MR. 2010. Involvement of dopaminergic and glutamatergic systems of the basolateral amygdala in amnesia induced by the stimulation of dorsal hippocampal cannabinoid receptors. *Neuroscience* **175**, 118-26.
<http://dx.doi.org/10.1016/j.neuroscience.2010.12.006>

Robinson L, Goonawardena AV, Pertwee RG, Hampson RE, Riedel G. 2007. The synthetic cannabinoid HU210 induces spatial memory deficits and suppresses hippocampal firing rate in rats. *British Journal of Pharmacology* **151**, 688-
<http://dx.doi.org/10.1038/sj.bjp.0707273>

Rodrigues SM, Schafe GE, LeDoux JE. 2004. Molecular mechanisms underlying emotional learning and memory in the lateral amygdala. *Neuron* **4**, 75-91.
<http://dx.doi.org/10.1016/j.neuron.2004.09.014>

Sarkisyan G, Hedlund PB. 2009. The 5-HT₇ receptor is involved in allocentric spatial memory information processing. *Behavioural Brain Research* **202**, 26-31.

<http://dx.doi.org/10.1016/j.bbr.2009.03.011>

Smith HR, Daunais JB, Nader MA, Porrino LJ. 1999. Distribution of [³H] citalopram binding sites in the nonhuman primate brain. *Annals of the New York Academy of Sciences* **877**, 700-2.
<http://dx.doi.org/10.1111/j.17496632.1999.tb09305.x>

Stern CA, Do Monte FH, Gazarini L, Carobrez AP, Bertoglio LJ. 2010. Activity in prelimbic cortex is required for adjusting the anxiety response level during the elevated plus-maze retest. *Neuroscience* **170**, 214-22.
<http://dx.doi.org/10.1016/j.neuroscience.2010.06.080>

Schafe GE, Doyere V, LeDoux JE. 2005. Tracking the fear engram: the lateral amygdala is an essential locus of fear memory storage. *Journal of Neuroscience* **25**, 10010-4.
<http://dx.doi.org/10.1523/JNEUROSCI.3307-05.2005>

Varvel SA, Lichtman AH. 2002. Evaluation of CB₁ receptor knockout mice in the Morris water maze. *Journal of Pharmacology and Experimental Therapeutics* **301**, 915-24.
<http://dx.doi.org/10.1124/jpet.301.3.915>

Viveros MP, Llorente R, Moreno E, Marco EM. 2005. Behavioural and neuroendocrine effects of cannabinoids in critical developmental periods. *Behavior Pharmacology* **16**, 353-62.
<http://dx.doi.org/10.1097/00008877-200509000-00007>

Walker DL, Toufexis DJ, Davis M. 2003. Role of the bed nucleus of the stria terminalis versus the amygdala in fear, stress, and anxiety. *European Journal of Pharmacology* **463**, 199-216.
[http://dx.doi.org/10.1016/S0014-2999\(03\)01282-2](http://dx.doi.org/10.1016/S0014-2999(03)01282-2)

Wilson RI, Nicoll RA. 2002. Endocannabinoid signaling in the brain. *Science* **296**, 678-82.
<http://dx.doi.org/10.1126/science.1063545>

Wilson DM, Peart J, Martin BR, Bridgen DT, Byron PR, Lichtman AH. 2002. Physiochemical and pharmacological characterization of a Delta(9)-THC aerosol generated by a metered dose inhaler. *Drug and Alcohol Dependence* **67**, 259-67.

[http://dx.doi.org/10.1016/S0376-8716\(02\)00078-9](http://dx.doi.org/10.1016/S0376-8716(02)00078-9)

Yang KH, Isaev D, Morales M, Petroianu G, Galadari S, Oz M. 2010. The effect of Delta9-tetrahydrocannabinol on 5-HT₃ receptors depends on the current density. *Neuroscience* **171**, 9-40.

<http://dx.doi.org/10.1016/j.neuroscience.2010.08.044>

Zarrindast MR, Ghiasvand M, Rezayof A, Ahmadi S. 2007. The amnesic effect of intra-central amygdala administration of a cannabinoid CB₁ receptor agonist, WIN55,212-2, is mediated by a beta-1 noradrenergic system in rat. *Neuroscience* **212**, 77-85.

<http://dx.doi.org/10.1016/j.neuroscience.2012.04.008>

Zarrindast MR, Navaeian M, Nasehi M. 2010. Influence of three-day morphine-treatment upon impairment of memory consolidation induced by cannabinoid infused into the dorsal hippocampus in rats. *Neuroscience Research* **69**, 51-9.

<http://dx.doi.org/10.1016/j.neures.2010.09.007>

Zarrindast MR, Dorrani M, Lachinani R, Rezayof A. 2010. Blockade of dorsal hippocampal dopamine receptors inhibits state-dependent learning induced by cannabinoid receptor agonist in mice. *Neuroscience Research* **67**, 25-32.

<http://dx.doi.org/10.1016/j.neures.2010.02.001>

Zarrindast MR, Nouri M, Ahmadi S. 2007. Cannabinoid CB₁ receptors of the dorsal hippocampus are important for induction of

conditioned place preference (CPP) but do not change morphine CPP. *Brain Research* **1163**, 130-7.

<http://dx.doi.org/10.1016/j.brainres.2007.06.015>

Zarrindast MR, Sroushi A, Bananej M, Vouseoghi N, Hamidkhaniha S. 2011. Involvement of the dopaminergic receptors of the rat basolateral amygdala in anxiolytic-like effects of the cholinergic system. *European Journal of Pharmacology* **672**, 106-12.

<http://dx.doi.org/10.1016/j.ejphar.2011.09.168>

Zarrindast MR, Nasehi M, Khansari M, Bananej M. 2010. Influence of nitric oxide agents in the rat amygdala on anxiogenic-like effect induced by histamine. *Neuroscience Letters* **489**, 38-42.

<http://dx.doi.org/10.1016/j.neulet.2010.11.062>

Zarrindast MR, Mahboobi S, Sadat-Shirazi MS, Ahmadi S. 2010. Anxiolytic-like effect induced by the cannabinoid CB₁ receptor agonist, arachydonilcyclopropylamide (ACPA), in the rat amygdala is mediated through the D₁ and D₂ dopaminergic systems. *Journal of Psychopharmacology* **25**, 131-40.

<http://dx.doi.org/10.1177/0269881110376688>

Zarrindast MR, Sarahroodi S, Arzi A, Khodayar MJ, Taheri-Shalmani S, Rezayof A. 2008. Cannabinoid CB₁ receptors of the rat central amygdala mediate anxiety-like behavior: interaction with the opioid system. *Behavioral Pharmacology* **19**, 716-23.

<http://dx.doi.org/10.1097/FBP.0b013e3283123e83>

Zarrindast MR, Valizadegan F, Rostami P, Rezayof A. 2008. Histaminergic system of the lateral septum in the modulation of anxiety-like behaviour in rats. *European Journal of Pharmacology* **583**, 108-14.

<http://dx.doi.org/10.1016/j.ejphar.2008.01.003>